EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential

Zhi Xu iD, Junna Liu

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70178 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Zhi Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Huanghuai University Industry Innovation & Research and Development Institute, Huanghuai University, Zhumadian, Henan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hydroxamic Acids, Histone Deacetylase Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: Huanghuai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer, as a fatal metastatic disease, exerts a deep‐seated and extensive influence on human health, impacting not just the physical condition of patients but also their psychological state and social lives. Hydroxamic acid derivatives, as exceptional histone deacetylase (HDAC) inhibitors, could regulate diverse cellular pathways, cause cell cycle arrest, and promote programmed cell death. Consequently, hydroxamic acid derivatives demonstrate significant efficacy in combating a wide range of cancers, including hematological malignancies and solid tumors. Moreover, diverse hydroxamic acid derivatives have already been applied in clinics or are currently undergoing clinical trials for cancer therapy, revealing that hydroxamic acid derivatives hold great promise as scaffolds for exploring novel anticancer agents. This review aims to comprehensively summarize the current scenario of hydroxamic acid derivatives with in vivo antitumor therapeutic potential, along with their metabolic profiles, pharmacokinetic properties, toxicity, and mechanisms of action, developed since 2020, to facilitate further rational design of safer and more potent candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsHydroxamic AcidsHistone Deacetylase InhibitorsNeoplasmsHumansAnimalsStructure-Activity RelationshipMolecular Structure

Stichwörter der Autor:innen

histone deacetylaseshybrid moleculeshydroxamic acidin vivo efficacymechanisms of actiontumor

Substanzen

Antineoplastic AgentsHydroxamic AcidsHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • Huanghuai University Industry Innovation & Research and Development Institute, Huanghuai University, Zhumadian, Henan, China.
  • School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China.

ORCID-Profile: Zhi Xu

Förderung

  • Huanghuai University

Zitieren

APA

Xu, Z., & Liu, J. (2025). Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70178

Vancouver

Xu Z, Liu J. Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70178

BibTeX
@article{Xu2025,
  author = {Xu, Zhi and Liu, Junna},
  title = {Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70178}
}
Kostenlos starten →